Luliconazole

Bezeichnung:Luliconazole

CAS-Nr187164-19-8

Englisch Name:Luliconazole

CBNumberCB01120404

SummenformelC14H9Cl2N3S2

Molgewicht354.27

MOL-Datei187164-19-8.mol

Luliconazole physikalisch-chemischer Eigenschaften

Schmelzpunkt	152 °C
Siedepunkt	499.1±55.0 °C(Predicted)
Dichte	1.52±0.1 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
Löslichkeit	Chloroform (Slightly), Ethyl Acetate (Slightly)
Aggregatzustand	Solid
pka	3.76±0.10(Predicted)
Farbe	White to Off-White
Stabilität	Light Sensitive
CAS Datenbank	187164-19-8

Sicherheit

HS Code

2933.29.2000

Gefahreninformationscode (GHS)

Luliconazole Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Luliconazole is a member of the imidazole class of antifungal agents, with specific utility as a dermatological antimycotic drug. It was launched in Japan as a topical agent for the treatment of athlete’s foot. Luliconazole is an optically active drug with (R)-configuration at its chiral center. It is structurally related to lanoconazole, which has been marketed as a racemic mixture since 1994. As with other azole antifungal drugs, the mechanism of action of luliconazole is the inhibition of sterol 14-a-demethylase, and subsequently, inhibition of ergosterol biosynthesis. The in vivo activity of luliconazole against dermatophytes has been evaluated in the guinea pig model of tinea pedis. In this study, a 1% topical solution of luliconazole, administered once daily for seven days, achieved complete mycologic cure. Additionally, there were no occurrences of relapse for up to 16 weeks after the treatment. No data is currently available on the clinical efficacy of luliconazole. The chemical synthesis of luliconazole involves the condensation of 1-(cyanomethyl)imidazole with carbon disulfide to produce a dithioate intermediate, and subsequent alkylation with either the mesylate derivative of (S′)-1-(2,4-dichlorophenyl)-2-bromoethanol or the bis-mesylate derivative of (S′)-1-(2,4-dichlorophenyl)ethane-1,2-diol. .
Originator
Nihon Nohyaku (Japan)
Verwenden
Luliconazole is an azole antifungal drug. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Definition
ChEBI: Luliconazole is a dichlorobenzene.
Trademarks
Lulicon
Synthese
Synthesis of luliconazole started with diol 77, prepared according to literature procedure in 98%ee which was activated by converting to dimesylate 78 in 99% yield and coupled to dipotassium enolate 80, prepared in situ by reacting cyano methylimidazole 79 with carbon disulfide, to give luliconazole (XI), 99% ee in 48% yield.
Mode of action
The mechanism of action of luliconazole is as a Cytochrome P450 2C19 Inhibitor.

Luliconazole Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

187164-19-8, Luliconazole Verwandte Suche:

Send Inquriy